Blogs & News

FDA-approval granted to Huvepharma® for feed additive CycleGuard® 500 (melengestrol acetate Type A liquid medicated article)

PEACHTREE CITY, GA (June 24, 2020) — Huvepharma® has received FDA-approval for CycleGuard® 500, a melengestrol acetate feed additive used for suppression of estrus in heifers.

Available as a Type A liquid medicated article, CycleGuard® 500 is a bio-equivalent product to MGA® and HeiferMaX®, meaning it provides the same benefits of dosage, chemical identity, potency, quality and safety to these existing melengestrol acetate brands.

CycleGuard® 500 can be used to suppress estrus in heifers intended for breeding as well as to suppress estrus among heifers fed in confinement intended for slaughter. For feedlot heifers, melengestrol acetate is also proven to increase rate of weight gain and improve feed efficiency. CycleGuard® 500 must be mixed with other feeds when fed and be fed according to label directions.

“We are excited to bring more products to the U.S. cattle industry as we continue to rapidly expand our Huvepharma portfolio,” notes Glen Wilkinson, president of Huvepharma U.S. He adds, “Huvepharma is focused on offering quality product choices and technical expertise to livestock producers and feeders to aid the industry in enhancing production and efficiency. CycleGuard® 500 is one more tool available toward that effort.”

Huvepharma has offered animal health products for cattle, swine and poultry in the U.S. since 2005. In addition to CycleGuard® 500, over the past year, the company has received FDA approvals for Monovet® 90 (monensin), the first available bio-equivalent monensin, and Optigrid® 45 (ractopamine HCl), as well as launched RESPIVaxTM, a new BRD vaccine.

Throughout the U.S., Huvepharma is focused on building partnerships with industry customers by offering high quality products and unparalleled customer service. For more information and complete labeling information, please contact your Huvepharma sales representative and/or Huvepharma’s Customer Service team at 877-994-4883 or visit www.huvepharma.us.


IMPORTANT SAFETY INFORMATION: CYCLEGUARD® 500 (melengestrol acetate Type A liquid medicated article): Not effective in steers or spayed heifers.  Withdrawal periods of three to five days or more should be avoided to prevent the possibility that the heifers may come into estrus (heat) at loading time. When used in heifers intended for breeding, do not exceed 24 days. A reduced conception rate can be expected within 1 to 12 days after the withdrawal of melengestrol acetate. Heifers bred on subsequent observed estruses will have normal conception rates. To report adverse effects, access medical information, or obtain additional product information, call 1-877-426-7765. View product label here.

IMPORTANT SAFETY INFORMATION OPTIGRID® 45 (ractopamine hydrochloride Type A medicated article): Not for human use. For use in feeds for cattle fed in confinement for slaughter. Not for animals intended for breeding.  No withdrawal is necessary if directions are followed. The active ingredient in Optigrid 45, ractopamine hydrochloride, is a Beta-adrenergic agonist. Individuals with cardiovascular disease should exercise special caution to avoid exposure. Not for use in humans. Keep out of the reach of children. The Optigrid 45 formulation (Type A Medicated Article) poses a low dust potential under usual conditions of handling and mixing. When mixing and handling Optigrid 45 use protective clothing, impervious gloves, protective eye wear, and a NIOSH-approved dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse eyes thoroughly with water. If irritation persists, seek medical attention. The Safety Data Sheet (SDS) contains more detailed occupational safety information. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Huvepharma, Inc. at 1-877-994-4883 or www.huvepharma.us. View product label here.

IMPORTANT SAFETY INFORMATION: MONOVET® 90 (monensin Type A medicated article): Not for Human Use.  Do not allow horses or other equines access to feeds containing monensin. Ingestion of monensin by horses has been fatal. Consumption by unapproved species may result in toxic reactions and even fatalities.  A withdrawal time has not been established for pre-ruminating calves.  Do not use in calves to be processed for veal.  When mixing and handling Monovet 90, use protective clothing, impervious gloves and a dust mask.  Operators should wash thoroughly with soap and water after handling.  If accidental eye contact occurs, immediately rinse with water.  To report adverse effects, access medical information, or obtain additional product information, call 1-877-426-7765. View product label here.

About Huvepharma

Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. A privately-owned company with U.S. headquarters in Peachtree City, Georgia, Huvepharma is based in Sofia, Bulgaria. Learn more about Huvepharma and its products at https://huvepharma.us/.

Huvepharma is a registered trademark of Huvepharma EOOD.

Huvepharma, Monovet, Optigrid, RESPIVax and Cycleguard are registered trademarks of Huvepharma EOOD.

MGA® is a registered trademark of Zoetis Services LLC.

HeiferMaX® is a registered trademark of Elanco US Inc.